NCT07663747
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07663747
Title Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC (FIDELIO)
Acronym FIDELIO
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors The Netherlands Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD

Facility Status City State Zip Country Details
Antoni van Leeuwenhoek ziekenhuis Amsterdam Netherlands Details
Leiden University Medical Center Leiden (LUMC) Leiden Netherlands Details
University Medical Center Utrecht(UMCU) Utrecht Netherlands Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field